The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 30, 2024

Filed:

Feb. 09, 2023
Applicant:

Somerset Therapeutics, Llc, Hollywood, FL (US);

Inventors:

Mandar V. Shah, Rockaway, NJ (US);

Ilango Subramanian, Warren, NJ (US);

Veerappan Subramanian, Warren, NJ (US);

Aman Trehan, Hillsborough, NJ (US);

Assignee:

Somerset Therapeutics, LLC, Hollywood, FL (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4178 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/14 (2006.01); A61K 31/498 (2006.01); A61K 47/02 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 47/44 (2017.01);
U.S. Cl.
CPC ...
A61K 31/4178 (2013.01); A61K 9/0048 (2013.01); A61K 9/08 (2013.01); A61K 31/14 (2013.01); A61K 31/498 (2013.01); A61K 47/02 (2013.01); A61K 47/186 (2013.01); A61K 47/26 (2013.01); A61K 47/44 (2013.01);
Abstract

The present invention provides relatively low pH, stable, pharmaceutically acceptable and ophthalmologically suitable compositions comprising effective amounts of pilocarpine and brimonidine compounds for treating an ocular condition, wherein compositions demonstrate a significant difference in the amount or rate of one or more pharmaceutical ingredient(s) absorbed or retained by ocular tissue or compared to reference composition(s) with similar compositional characteristics but having a significantly higher pH. In aspects compositions are characterizable by other elements, e.g., the inclusion of benzalkonium chloride, a limited amount of sodium chloride, or both. In embodiments, compositions are free of both a borate and a citrate buffer. Compositions provided by the invention surprisingly demonstrate pharmaceutically acceptable stability when stored under controlled room temperature conditions for an extended period of time. Further, the invention provides methods of manufacturing such compositions in liquid (solution) and gel forms, and methods of their use in treating conditions such as presbyopia.


Find Patent Forward Citations

Loading…